RT Journal Article
SR Electronic
T1 Kinetic modeling of Florbetaben (BAY 94-9172) binding to β-amyloid in human brains using one and two input functions
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 550
OP 550
VO 51
IS supplement 2
A1 Georg Becker
A1 Masanori Ichise
A1 Henryk Barthel
A1 Julia Luthardt
A1 Marianne Patt
A1 Marcus Schultze-Mosgau
A1 Cornelia Reininger
A1 Ulrich Hegerl
A1 H. Gertz
A1 Osama Sabri
YR 2010
UL http://jnm.snmjournals.org/content/51/supplement_2/550.abstract
AB 550 Objectives Florbetaben is a [18F]-labeled stilbene derivative which has great potential to detect β-amyloid in the living human brain. To investigate the influence of a possible metabolite passing the blood brain barrier, a kinetic modeling approach with two input functions was applied. Methods After i.v. administration of ~300 MBq Florbetaben, 10 subjects with Alzheimer's disease (AD) and 10 age-matched healthy volunteers (HV) underwent 3D-PET. Concentrations of parent compound and metabolites were determined in plasma and used as input functions. VOI-based tissue-activity curves (TACs) from 25 brain regions were analyzed using two tissue compartments with one input function (OIF) or three tissue compartments with two input functions (TIF) over a time range of 90 (OIF) and 200 (TIF) minutes. Also the reference tissue approach MRTM3 was applied. The kinetics of the metabolite(s) was described by one tissue compartment ("simplified" K1 fixed). DVR, BP_P and SUV-ratio were used to characterize specific binding (reference: cerebellar cortex). Effect size in group comparison was determined by Cohen's d. Results All TACs could be analyzed by the OIF- and TIF-approach with similar precision. Kinetic parameters associated with β-amyloid load were significantly higher in ADs compared to HVs, e.g. for the mean of frontal, lateral temporal, parietal and posterior cingulate cortices (AD n=8, HV n=9, with decreasing order of d) OIF: DVR=1.75±0.13 vs 1.28±0.11, d= 4.23; MRTM3: DVR=1.54±0.07 vs 1.18±0.11, d=4.11; SUV-ratio (70-90 min)=1.79±0.14 vs 1.30±0.12, d=4.03; OIF: BP_P=4.60±1.45 vs 1.44±0.45, d=3.22; TIF: DVR=2.62±0.89 vs 1.34±0.21, d=2.82; BP_P=4.27±2.05 vs 0.91±0.45, d=2.52. Conclusions For Florbetaben, DVRs computed with MRTM3 and SUV-ratios are parameters well suited to quantify β-amyloid deposition by means of PET. Research Support This trial was supported by Bayer Healthcare Berlin (Germany)